Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23009915 | 1.00 | CPB2 (0.38) | CPB2CYP4F2CYP4A11MAPTCRHBP | |
| SCHEMBL21244382 | 0.85 | CYP1A2 (0.40) | CPB2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL21244518 | 0.84 | KMT2A (0.40) | CPB2CYP4F2CYP4A11MAPTCRHBP | |
| SCHEMBL26938914 | 0.84 | KISS1R (0.38) | CPB2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL22975211 | 0.84 | L3MBTL1 (0.41) | CPB2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL21288571 | 0.83 | CPB2 (0.38) | CPB2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL22975200 | 0.81 | CHRM1 (0.36) | CPB2MAPK1KMT2ATDP1CA2 | |
| SCHEMBL26938920 | 0.81 | KISS1R (0.31) | — | |
| SCHEMBL22975199 | 0.81 | CHRM1 (0.36) | CPB2MAPK1KMT2ATDP1CA2 | |
| SCHEMBL26938919 | 0.81 | KISS1R (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122788-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4013741-B1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMA (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-114555556-B | Process for preparing CFTR modulators | 弗特克斯药品有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-11584761-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584761-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4013741-A1 | PROCESS OF MAKING CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555556-A | Methods of making CFTR modulators | 弗特克斯药品有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021030554-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030554-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | CPB2 4155/4885CYP4F2 2773/4885CYP4A11 1318/4885 |
| US-11584761-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | CPB2 4155/4885CYP4F2 2773/4885CYP4A11 1318/4885 |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | CPB2 4155/4885CYP4F2 2773/4885CYP4A11 1318/4885 |
| US-12122788-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | CPB2 4155/4885CYP4F2 2773/4885CYP4A11 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.